AUTHORS
Yiqi Li, Qiqi Zhang2, Yingjie Lu3, Liuhai Zheng4, Dongrui Wang5, He Huang, MD, PhD6
AFFILIATIONS
1 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
2 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
3 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
4 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
5 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
6 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
ABSTRACT
Background
In vivo generation of chimeric antigen receptor (CAR) T cells using lipid nanoparticles (LNPs) targeting T-cell surface proteins represents a promising strategy for cancer immunotherapy. However, current CD3-targeting approaches rely primarily on agonistic anti-CD3 antibodies that activate TCR signaling, leading to activation-induced cell death (AICD), T-cell depletion, and potential systemic toxicity. Alternative strategies targeting other T-cell surface proteins are limited by heterogeneous receptor expression, disease-associated receptor downregulation, or suboptimal delivery efficiency. Thus, it is critical to design new strategies that enables efficient T cell-targeted LNP delivery without causing excessive activation.
Methods & Results
To address these challenges, we used an AI-assisted screening platform to identify a non-activating CD3-binding ligand. Further functional analysis of the extracellular domain of the candidate protein through in vitro affinity validation identified a peptide with CD3-binding potential. Its binding specificity was verified using CD3-knockout Jurkat cells and via confocal microscopy. The peptide was then conjugated into LNPs (LNP-Pep), and the efficiency of transfecting T cells was evaluated between LNP-Pep and anti-CD3 antibody-conjugated LNPs (LNP-Ab). In both in vitro (primary human T cells) and in vivo (NCG mice engrafted with primary T cells) models, LNP-Pep was able to efficiently transfect T cells while reducing apoptosis compared to LNP-Ab. As a result, LNP-Pep transfection or injection led to generating of higher numbers of functional CAR-T cells.
Mechanistically, compared with LNP-Ab, LNP-Pep-transfected primary T cells showed lower expression of activation and exhaustion markers, including CD69, CD25, PD-1, TIM-3, and LAG-3. Phospho-flow cytometry further confirmed minimal activation of early TCR signaling, with markedly reduced phosphorylation of ZAP70, LAT, and PLCγ1. Transcriptomic profiling demonstrated reduced expression of activation- and apoptosis-related programs together with enrichment of naïve/memory-associated signatures.
Functionally, LNP-Pep-transfected CAR-T cells exhibited more sustained cytotoxic activity against Nalm6 B-ALL cells compared with LNP-Ab. In human PBMC-engrafted, Nalm6 leukemia-bearing NCG mice, CD19-CAR mRNA-loaded LNP-Pep achieved superior tumor control and greater in vivo T-cell expansion than unmodified LNP and LNP-Ab. Post-killing RNA-seq further revealed enrichment of pathways associated with proliferation, stemness, and effector function, accompanied by lower expression of inflammatory cytokines, in the LNP-Pep group, supporting both improved phenotypic fitness and functional enhancement.
Conclusion
Our study identifies a novel non-activating CD3-targeted peptide LNP platform that decouples CD3-mediated targeted mRNA delivery from TCR activation. By reducing activation-induced cell death while preserving T-cell viability and memory-associated characteristics, this strategy increases the absolute number of functional CAR-T cells generated through in vivo LNP-mediated delivery, and enhances antitumor efficacy. These findings support non-activating CD3 targeting as a promising approach for more effective in vivo CAR-T cell therapy.
DISCLOSURES
Yiqi Li: No relevant conflicts of interest to declare.